Physician profile
Yan Kiriakov
NPI 1467863324
$2,555.18
in general payments reported to CMS, 2019-2025
24 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $277 · 2021: $17.76 · 2022: $15.67 · 2023: $376 · 2024: $739 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.41 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $345.09 | 2023-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $300.63 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Qiagen, LLC | $258.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $249.41 | 2019-2020 | |
| Astellas Pharma US INC | $210.63 | 2024 | Veozah |
| Bausch Health US, LLC | $193.43 | 2024-2025 | Wellbutrin |
| Pfizer INC. | $137.96 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $124.61 | 2020 | |
| Exact Sciences Corporation | $122.14 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $116.21 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $97.94 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $71.40 | 2024-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $43.91 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $42.67 | 2024-2025 | Bodyguardian |
| Genentech USA, INC. | $38.85 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.15 | 2023-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $33.42 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $23.85 | 2025 | |
| Medicomp INC | $22.31 | 2025 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $19.40 | 2024 | Injectafer |
| Seqirus USA INC | $18.15 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Phathom Pharmaceuticals, INC. | $18.12 | 2024 | Voquezna |
| Nabriva Therapeutics, Plc | $15.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.98 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Kiriakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.